Our Transformation Talks Summer Special is here!
Next Generation Therapies (NGTs) currently in development will deliver treatments that address the underlying cause of diseases, disrupt the biopharmaceutical environment, and offer a life-long solution to patients. They create unprecedented opportunities for patients and will be measurable in lives saved, disabilities reduced, and overall quality of life improvements. However, along with these benefits come unprecedented challenges for insurance coverage, reimbursement, and payment.
Tune in to learn about risks and challenges in developing NGTs, bringing them to the market, and how NGTs can change patients’ lives once their value is understood and correctly attributed by the decision makers / payers.
The episode “The Promise and Reality of NGTs” is also available on the following platforms:
You can also learn more about next generation therapies in our latest white paper, Advanced Therapies Medicinal Products: Access, Pricing, and Ethical Issues in Perspective.
Oswald Bentinck
Vice President - Head of Market Access EMEA, Novartis Gene TherapiesPietro Sternini
Executive Director, Gene Therapy Market Access & Marketing Lead, EMEA, Astellas Gene TherapiesSubscribe to our newsletter for the latest news, events, and thought leadership